Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014
Feb 1, 2023 Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two... More |
Jan 25, 2023 Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m.... More |
Jan 25, 2023 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett... More |
Jan 4, 2023 --Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed,... More |
Nov 7, 2022 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its... More |
Nov 2, 2022 Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter... More |
Oct 26, 2022 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett... More |
Oct 21, 2022 Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic... More |
Oct 19, 2022 -Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA, Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced... More |
Aug 31, 2022 No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has... More |